The aim of this retrospective analysis was to investigate the effect of PCSK9 inhibitor therapy on markers of lipid metabolism, to determine patient characteristics, to assess the indications for their use and to evaluate the tolerance of PCSK9 inhibitor therapy in patients with and without T2D in a routine care-setting of an outpatient clinic in a tertiary care center. The gene discussed is PCSK9; the disease is type 2 diabetes mellitus.